Joined the Advent Ventures Life Sciences Team in 2007 as Venture Partner. One of Europe’s most successful Biotechnology entrepreneurs having founded and built three successful companies, Tibotec, Galapagos and Virco. Involved in assisting Advent portfolio companies in a variety of Board level roles, and in supporting the Investment team to source and assess new opportunities in Europe. A pharmaceutical scientist and entrepreneur who is currently at the Ecole Polytechnique Fédérale de Lausanne, one of the leading centres in Europe for micro-, nano- and bio-nanotechnology. In 1994, he co-founded Tibotec, and was CEO and CSO. Under his leadership, Tibotec rapidly grew into one of the most productive companies in the field of anti-HIV drug discovery. In 1995, co-founded Virco a company whose activities/technologies were aimed towards the improvement of the management of HIV/AIDS patients using new molecular diagnostic tools for HIV drug resistance monitoring. In 2002, Tibotec and Virco were acquired by Johnson & Johnson. Together with Dr D Valerio, initiated in 1999 the formation of Galapagos Genomics a joint-venture between Tibotec and Crucell (formerly known as IntroGene).
PhD from the University of Leuven in Belgium.
Acted as Chairman of Galapagos Genomics from 1999-2002. In 2007, joined again the board as independent director of the company which had become listed on Euronext.
RECORD ID: 33338